Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia

Pediatric Blood & Cancer
Lucie SramkovaJan Trka

Abstract

The level of minimal residual disease (MRD) prior to allogeneic hematopoietic stem cell transplantation (HSCT) has been shown to be an independent prognostic factor for outcome of pediatric patients with high-risk acute lymphoblastic leukemia (ALL). Retrospective studies which used (semi-) quantitation of clone-specific immunoglobulin/T-cell receptor (Ig/TCR) rearrangements have documented the feasibility and practicality of this technique. This approach has also been disputed due to the occurrence of clonal evolution and generally high MRD levels prior to HSCT. In our prospective study, MRD before and after HSCT was monitored using quantitative real-time PCR in a cohort of 36 children with ALL consecutively transplanted in our center between VIII/2000 and VII/2004. In 25 of 36 patients, MRD level prior HSCT was assessed. Seventeen patients were classified as MRD-negative and eight were MRD-positive up to 9 x 10(-2). In MRD-positive subgroup, seven events (six relapses) occurred post-transplant in striking contrast to only one relapse in MRD-negative subgroup (event-free survival (EFS) log-rank P < 0.0001). MRD proved to be the only significant prognostic factor in a multivariate analysis (P < 0.0001). Adoptive immunotherapy in...Continue Reading

References

May 28, 2004·Nature·Gerda EggerPeter A Jones
May 21, 2005·Nature Reviews. Drug Discovery·Ching-Hon PuiPeter Kirkpatrick
Jun 21, 2005·Nature Reviews. Drug Discovery·Ching-Hon Pui, Sima Jeha

❮ Previous
Next ❯

Citations

Apr 29, 2010·Current Hematologic Malignancy Reports·Veronica Jude, Ka Wah Chan
Nov 13, 2007·Bone Marrow Transplantation·P A Mehta, S M Davies
Jan 18, 2011·Hematology·Stella M Davies, Parinda A Mehta
Nov 19, 2010·Expert Review of Hematology·A John Barrett, Minoo Battiwalla
Sep 18, 2009·Pediatric Blood & Cancer·Ester MejstríkováOndrej Hrusák
Feb 5, 2008·Pediatric Clinics of North America·Rupert HandgretingerR Maarten Egeler
Jan 9, 2008·Seminars in Hematology·Charlotte M Niemeyer, Irith Baumann
Oct 22, 2008·Genes, Chromosomes & Cancer·Jan ZunaJan Trka
Mar 4, 2011·Pediatric Blood & Cancer·Jennifer H FosterBlythe Thomson
Jul 1, 2010·Genes, Chromosomes & Cancer·Jan ZunaJan Trka
Oct 15, 2014·British Journal of Haematology·Rosemary SuttonTracey A O'Brien
Mar 21, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Veronika BachanovaDaniel J Weisdorf
Jul 7, 2016·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ursula Jördis Eva SeidelPeter Lang
Dec 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suman MalempatiUNKNOWN Children's Oncology Group
Dec 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter BaderUNKNOWN ALL-REZ BFM Study Group
Dec 1, 2017·Pediatric Hematology and Oncology·Van HuynhMaureen M O'Brien
Apr 30, 2017·Molecular Diagnosis & Therapy·Michaela KotrovaMonika Brüggemann
Feb 6, 2018·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Divya SubburajRevathi Raj

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.